Novo Nordisk Shares Plunge After New Obesity Shot Disappoints
Novo Nordisk ’s big bet to improve on the success of its weight-loss drug franchise hit a stumbling block Friday, wiping out ...
Healthy Returns: Novo Nordisk's Ozempic faces scrutiny over potential link to rare eye condition
A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, ...
FiercePharma5d
After studies flag possible link between Novo's Ozempic and rare eye disorder, EU plans to investigate: Reuters
It’s not a new question, but it is one that is gaining increased traction: Is there a link between Novo Nordisk’s diabetes ...
Novo Nordisk's Ozempic faces EU review for potential eye disease connection
The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes ...
Why Novo Nordisk’s Stock Plunge Rattled Markets Today
Shares in Ozempic maker Novo Nordisk crashed, after an experimental anti-obesity shot fell short of expectations. The shares ...
STAT3d
What Novo Nordisk’s disappointing trial results mean for the obesity drug market
New clinical trial data from Novo Nordisk raise questions for the broad landscape of obesity drug development and the way ...
Novo Nordisk’s next-generation weight-loss drug matches Lilly’s Zepbound in major trial, but doesn’t surpass it
Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...
Novo Nordisk's Ozempic Wins Approval in Europe for Chronic Kidney Disease
Novo Nordisk ( NYSE:NVO) has secured approval from the European Medicines Agency (EMA) for a kidney disease-related label ...
Novo's Ozempic faces scrutiny over potential link to rare eye disease
Danish health authorities said on Monday they would ask the European Union's drug regulator to review the findings of two ...